{"title": "Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality - IOZK", "author": "Root", "url": "https://www.iozk.de/2023/03/autologous-dendritic-cell-vaccination-against-hiv-1-induces-changes-in-natural-killer-cell-phenotype-and-functionality/", "hostname": "iozk.de", "description": "PMID: 36864042 Journal: NPJ vaccines (volume: 8, issue: 1, NPJ Vaccines 2023 Mar;8(1):29) Published: 2023-03-02 Authors: Laeremans T, den Roover S, Lungu C, D\u2019haese S, Gruters RA, Allard SD, Aerts JL ABSTRACT Although natural killer (NK) cells have been studied in connection with dendritic cell (DC)-based vaccination in the field of cancer immunology, their role [\u2026]", "sitename": "IOZK", "date": "2023-03-02", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality ](https://www.iozk.de/2023/03/autologous-dendritic-cell-vaccination-against-hiv-1-induces-changes-in-natural-killer-cell-phenotype-and-functionality/)\nABSTRACT\nAlthough natural killer (NK) cells have been studied in connection with dendritic cell (DC)-based vaccination in the field of cancer immunology, their role has barely been addressed in the context of therapeutic vaccination against HIV-1. In this study, we evaluated whether a therapeutic DC-based vaccine consisting of monocyte-derived DCs electroporated with Tat, Rev and Nef encoding mRNA affects NK cell frequency, phenotype and functionality in HIV-1-infected individuals. Although the frequency of total NK cells did not change, we observed a significant increase in cytotoxic NK cells following immunisation. In addition, significant changes in the NK cell phenotype associated with migration and exhaustion were observed together with increased NK cell-mediated killing and (poly)functionality. Our results show that DC-based vaccination has profound effects on NK cells, which highlights the importance of evaluating NK cells in future clinical trials looking at DC-based immunotherapy in the context of HIV-1 infection.", "language": null, "image": null, "pagetype": "article", "links": ["https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.primomedico.com/fr/medecin/iozk-centre-immunologie-et-oncologie-de-cologne/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.primomedico.com/ar/tabib/iozk-mrkz-elm-almnaep-alsrtany-fy-koln/", "mailto:info@iozk.de", "https://www.iozk.de/2023/03/autologous-dendritic-cell-vaccination-against-hiv-1-induces-changes-in-natural-killer-cell-phenotype-and-functionality/", "https://www.iozk.de/en/", "https://www.iozk.de/es/", "https://www.iozk.de/ru/", "https://www.iozk.de/pl/", "https://www.iozk.de/", "/", "#", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "#", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "#", "https://www.iozk.de/iozk-publikationen/", "https://www.iozk.de/publikationen/", "https://www.iozk.de/fachwissen/", "https://www.iozk.de/aktuelles/", "https://www.iozk.de/kontakt/", "?s=", "#", "https://www.iozk.de/2023/03/autologous-dendritic-cell-vaccination-against-hiv-1-induces-changes-in-natural-killer-cell-phenotype-and-functionality/", "https://www.iozk.de/category/publications/dendritic-cells/", "https://www.iozk.de/category/publications/glioblastoma/", "https://www.iozk.de/category/publications/", "#", "https://www.ncbi.nlm.nih.gov/pubmed/36864042", "mailto:?subject=Autologous%20dendritic%20cell%20vaccination%20against%20HIV-1%20induces%20changes%20in%20natural%20killer%20cell%20phenotype%20and%20functionality&body=https://www.iozk.de/2023/03/autologous-dendritic-cell-vaccination-against-hiv-1-induces-changes-in-natural-killer-cell-phenotype-and-functionality/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/portfolio-item/evidenzbasierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/laboratorien-am-iozk/", "https://www.iozk.de/portfolio-item/magazin-der-iozk-stiftung-consilium/", "https://www.iozk.de/portfolio-item/video-patient-berichtet-ueber-die-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-patientin-frau-ebel-ueber-ihre-erfahrungen-mit-der-iozk-immuntherapie/", "https://www.iozk.de/portfolio-item/video-immunologische-krebstherapie-am-iozk-in-koeln/", "https://www.iozk.de/portfolio-item/informationsbroschuere-der-iozk-stiftung/", "https://www.iozk.de/portfolio-item/personalisierte-medizin-am-iozk/", "https://www.iozk.de/portfolio-item/die-entstehung-von-krebs/", "https://www.iozk.de/portfolio-item/was-bedeutet-immuntherapie/", "https://www.iozk.de/portfolio-item/nobelpreise-fuer-immuntherapie/", "https://www.iozk.de/portfolio-item/curcumin-in-der-medizinischen-anwendung/", "https://www.iozk.de/portfolio-item/virotherapie-mit-viren-gegen-den-krebs/", "https://www.iozk.de/portfolio-item/dendritische-zellen-informieren-das-immunsystem/", "https://www.iozk.de/portfolio-item/hyperthermie-mit-waerme-gegen-krebs/", "https://www.iozk.de/tag/brustkrebs/", "https://www.iozk.de/tag/case-report/", "https://www.iozk.de/tag/check-point-inibitoren/", "https://www.iozk.de/tag/chemotherapie/", "https://www.iozk.de/tag/curamun/", "https://www.iozk.de/tag/curcumin/", "https://www.iozk.de/tag/dendritische-zellen/", "https://www.iozk.de/tag/dr-dirk-lorenzen/", "https://www.iozk.de/tag/dr-wilfried-stuecker/", "https://www.iozk.de/tag/evidenzbasierte-medizin/", "https://www.iozk.de/tag/fluessigbiopsie/", "https://www.iozk.de/tag/german-medical-award/", "https://www.iozk.de/tag/glioblastom/", "https://www.iozk.de/tag/hirntumor/", "https://www.iozk.de/tag/hyperthermie/", "https://www.iozk.de/tag/immuntherapie/", "https://www.iozk.de/tag/io-vac/", "https://www.iozk.de/tag/iozk-symposium/", "https://www.iozk.de/tag/iozk-arbeitsgruppe/", "https://www.iozk.de/tag/iozk-immuntherapie/", "https://www.iozk.de/tag/iozk-patientenbroschuere/", "https://www.iozk.de/tag/iozk-stiftung/", "https://www.iozk.de/tag/newcastle-disease-virus/", "https://www.iozk.de/tag/nobelpreis-fuer-medizin/", "https://www.iozk.de/tag/onkologie/", "https://www.iozk.de/tag/onkolytische-viren/", "https://www.iozk.de/tag/paul-ehrlich-preis/", "https://www.iozk.de/tag/personalisierte-medizin/", "https://www.iozk.de/tag/ponsgliom/", "https://www.iozk.de/tag/prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/prostatakrebs/", "https://www.iozk.de/tag/publikationen-dr-wilfried-stuecker/", "https://www.iozk.de/tag/publikationen-prof-dr-rer-nat-volker-schirrmacher/", "https://www.iozk.de/tag/publikationen-stefaan-van-gool-md-phd/", "https://www.iozk.de/tag/stefaan-van-gool/", "https://www.iozk.de/tag/target-therapie/", "https://www.iozk.de/tag/virotherapie/", "tel:004922142039925", "mailto:info@iozk.de", "https://www.iozk.de/immuntherapie-gegen-krebs/philosophie/", "https://www.iozk.de/immuntherapie-gegen-krebs/team-iozk/", "https://www.iozk.de/immuntherapie-gegen-krebs/behandlungszentrum/", "https://www.iozk.de/immuntherapie-gegen-krebs/laboratorien/", "https://www.iozk.de/karriere/", "https://www.iozk.de/anreise/", "https://www.iozk.de/patientenbroschuere/", "https://www.iozk.de/die-iozk-immuntherapie/iozk-immuntherapie/", "https://www.iozk.de/die-iozk-immuntherapie/io-vac-impfstoff/", "https://www.iozk.de/die-iozk-immuntherapie/behandlungsablauf/", "https://www.iozk.de/die-iozk-immuntherapie/therapieverlauf-nach-krebsarten/", "https://www.iozk.de/immuntherapie-gegen-krebs/therapiekosten/", "https://www.iozk.de/die-iozk-immuntherapie/faq/", "https://www.iozk.de/2023/05/efficacy-of-a-dual-epitope-dendritic-cell-vaccine-as-part-of-combined-immunotherapy-for-her2-expressing-breast-tumors/", "https://www.iozk.de/2023/05/autologous-dendritic-cells-loaded-with-antigens-from-self-renewing-autologous-tumor-cells-as-patient-specific-therapeutic-cancer-vaccines/", "https://www.iozk.de/2023/04/dendritic-cell-vaccines-in-breast-cancer-immune-modulation-and-immunotherapy/", "https://www.iozk.de/impressum/", "https://www.iozk.de/datenschutzerklaerung/", "https://www.iozk.de/datenschutz/#BorCook", "https://www.iozk.de/presse/", "#top"]}